Protein-biomarker Dx Firm Astute Medical Raises $26.5M

"With this financing, the resources are in place to conduct clinical studies that will move us closer to commercialization of promising diagnostic products currently in development," the company's CEO said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.